Lykos Therapeutics, the developer of psychedelic drugs for mental health conditions that has been in financial difficulty, ...

周二，专注于迷幻药研究的生物科技公司Mind ...

Mind Medicine (NASDAQ: MNMD) stock is posting big gains in Tuesday's trading. The biotech company's share price was up 8.7% ...

Mescaline is under clinical development by Mind Medicine MindMed and currently in Phase I for Unspecified Psychiatric Disorders.

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase I for Pain.

One or two doses of psilocybin, a compound found in psychedelic mushrooms, may improve the mental health of cancer patients when accompanied by psychotherapy, a new study suggests. A second new study ...

Geode Capital Management LLC boosted its holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 10.8% during ...

GET MORE AI-GENERATED SIGNALS: December 29, 2024, 13:56 pm ET, BY John- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

Inc. (NASDAQ:MNMD – Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded ...

On Friday, Mind Medicine (MindMed) Inc (MNMD) stock saw a decline, ending the day at $6.84 which represents a decrease of $-0.79 or -10.35% from the prior close of $7.63. The stock opened at $7.57 and ...

在其他最近的新闻中，生物制药公司Mind Medicine (MindMed)有了重大进展。该公司用于治疗广泛性焦虑障碍的实验性治疗MM120 ODT获得了英国药品和保健品监管局的创新通行证。MindMed还进行了关键的高管任命，欢迎Javier A. Muniz博士担任研发战略副总裁，Gregg A. Pratt博士担任首席监管和质量保证官。

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)的首席医疗官Dan Karlin最近出售了公司6,643股普通股。该公司是一家市值5.02亿美元的生物科技公司，其股票在过去一年中上涨超过100%。根据 InvestingPro 的数据，分析师对MNMD保持看好态度，多项关键指标显示公司财务状况良好。这次出售是在2024年12月26日执行的，属于根据规则10b5- ...